Skip to main content
Erschienen in:

29.03.2021 | Original article

CLB add-on treatment in patients with epileptic encephalopathy: a single center experience with long-term follow-up

verfasst von: Dilşad Türkdoğan, Gülten Öztürk

Erschienen in: Acta Neurologica Belgica | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Abstract

Clobazam (CLB) is an effective anticonvulsant used as an adjunctive treatment for several seizures and epilepsy syndromes. Data are limited on efficacy and safety of CLB as add-on therapy for epileptic encephalopaties (EEs) other than Lennox-Gastaut syndrome (LGS). This retrospective study aimed to assess efficacy and safety of long-term CLB add-on therapy for various EE syndromes. Data on CLB add-on therapy were assessed in 74 children (60.8% male) after 3 months (early) and 12 months (late) follow-up as well as in 57 (77%) patients who had been on CLB therapy longer than 12 months (mean:39.11 ± 30.29; range:12–129 months) (very late) were reported. Data on CLB add-on therapy were assessed in 74 children (60.8% male) after 3 months (early) and 12 months (late) follow-up as well as in 57 (77%) patients who had been on CLB therapy longer than 12 months (mean:39.11 ± 30.29; range:12–129 months) (very late) were reported. Good response rate (> 50%) for seizures was achieved in 24% at early follow-up, 30% at late follow-up, and 35% during very late follow-up. Complete seizure remission was achieved for 15% seizures; 72.7% occurred at very late follow-up. Myoclonic seizures were the most responsive (35%); this response increased during late follow-up (46%), whereas 27.3% of myoclonic-atonic/atonic seizures had good response at early and very late follow-up. At late follow-up, comparison of mean effective doses of CLB did not show significant difference among types of seizures with good response. Adverse effects reported in 15% of patients did not require stopping CLB therapy. Generalized epileptogenic potentials significantly decreased while focal epileptogenic potentials significantly increased at first year of treatment in comparison to basal EEG findings (p < 0.001). CLB should be considered as an optional antiepileptic that is well tolerated, particularly in EEs with myoclonic and myoclonic-atonic/atonic seizures.
Literatur
1.
Zurück zum Zitat Gastaut H, Low MD (1979) Antiepileptic properties of clobazam, a 1–5 benzodiazepine, in man. Epilepsia 20(4):437–444CrossRef Gastaut H, Low MD (1979) Antiepileptic properties of clobazam, a 1–5 benzodiazepine, in man. Epilepsia 20(4):437–444CrossRef
2.
Zurück zum Zitat Riss J, Cloyd J, Gates J, Collins S (2008) Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand 118(2):69–86CrossRef Riss J, Cloyd J, Gates J, Collins S (2008) Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand 118(2):69–86CrossRef
3.
Zurück zum Zitat Munn R, Farrell K (1993) Open study of clobazam in refractory epilepsy. Pediatr Neurol 9(6):465–469CrossRef Munn R, Farrell K (1993) Open study of clobazam in refractory epilepsy. Pediatr Neurol 9(6):465–469CrossRef
4.
Zurück zum Zitat Perry MS, Bailey L, Malik S et al (2013) Clobazam for the treatment of intractable epilepsy in children. J Child Neurol 28(1):34–39CrossRef Perry MS, Bailey L, Malik S et al (2013) Clobazam for the treatment of intractable epilepsy in children. J Child Neurol 28(1):34–39CrossRef
5.
Zurück zum Zitat Jan MM, Shaabat AO (2000) Clobazam for the treatment of intractable childhood epilepsy. Saudi Med J 21(7):622–624PubMed Jan MM, Shaabat AO (2000) Clobazam for the treatment of intractable childhood epilepsy. Saudi Med J 21(7):622–624PubMed
6.
Zurück zum Zitat Ng YT, Conry J, Paolicchi J et al (2012) Long-term safety and efficacy of clobazam for Lennox-Gastaut syndrome: interim results of an open-label extension study. Epilepsy Behav 25(4):687–694CrossRef Ng YT, Conry J, Paolicchi J et al (2012) Long-term safety and efficacy of clobazam for Lennox-Gastaut syndrome: interim results of an open-label extension study. Epilepsy Behav 25(4):687–694CrossRef
7.
Zurück zum Zitat Michael B, Marson AG (2008) Clobazam as an add-on in the management of refractory epilepsy. Cochrane Database Syst Rev 16(2):004154 Michael B, Marson AG (2008) Clobazam as an add-on in the management of refractory epilepsy. Cochrane Database Syst Rev 16(2):004154
8.
Zurück zum Zitat Canadian Study Group for Childhood Epilepsy (1998) Clobazam has equivalent efficacy to carbamazepine and phenytoin as monotherapy for childhood epilepsy. Epilepsia 39(9):952–959CrossRef Canadian Study Group for Childhood Epilepsy (1998) Clobazam has equivalent efficacy to carbamazepine and phenytoin as monotherapy for childhood epilepsy. Epilepsia 39(9):952–959CrossRef
9.
Zurück zum Zitat Shimizu H, Abe J, Futagi Y et al (1982) Antiepileptic effects of clobazam in children. Brain Dev 4(1):57–62CrossRef Shimizu H, Abe J, Futagi Y et al (1982) Antiepileptic effects of clobazam in children. Brain Dev 4(1):57–62CrossRef
10.
Zurück zum Zitat Canadian Clobazam Cooperative Group (1991) Clobazam in treatment of refractory epilepsy: the Canadian experience. A retrospective study. Epilepsia 32(3):407–416CrossRef Canadian Clobazam Cooperative Group (1991) Clobazam in treatment of refractory epilepsy: the Canadian experience. A retrospective study. Epilepsia 32(3):407–416CrossRef
11.
12.
Zurück zum Zitat Ng YT, Conry JA, Drummond R et al (2011) OV-1012 Study Investigators. Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome. Neurology 77(15):1473–1481CrossRef Ng YT, Conry JA, Drummond R et al (2011) OV-1012 Study Investigators. Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome. Neurology 77(15):1473–1481CrossRef
13.
Zurück zum Zitat Berg AT, Berkovic SF, Brodie MJ et al (2010) Revised terminology and concepts Commission on Classification and Terminology, 2005–2009. Epilepsia 51(4):676–685CrossRef Berg AT, Berkovic SF, Brodie MJ et al (2010) Revised terminology and concepts Commission on Classification and Terminology, 2005–2009. Epilepsia 51(4):676–685CrossRef
14.
Zurück zum Zitat Kwan P, Arzimanoglou A, Berg AT et al (2010) Definition of drug resistant epilepsy: consensus proposal by the ad hoc task force of the ILAE commission on therapeutic strategies. Epilepsia 51(6):1069–1077CrossRef Kwan P, Arzimanoglou A, Berg AT et al (2010) Definition of drug resistant epilepsy: consensus proposal by the ad hoc task force of the ILAE commission on therapeutic strategies. Epilepsia 51(6):1069–1077CrossRef
15.
Zurück zum Zitat Fisher RS, Cross H, D’Souza C et al (2017) Instruction manual for the ILAE 2017 operational classification of seizure types. Epilepsia 58(4):531–542CrossRef Fisher RS, Cross H, D’Souza C et al (2017) Instruction manual for the ILAE 2017 operational classification of seizure types. Epilepsia 58(4):531–542CrossRef
16.
Zurück zum Zitat Loscher W, Schmidt D (2006) Experimental and clinical evidence for loss of effect (tolerance) during prolonged treatment with antiepileptic drugs. Epilepsia 47:1253–1284CrossRef Loscher W, Schmidt D (2006) Experimental and clinical evidence for loss of effect (tolerance) during prolonged treatment with antiepileptic drugs. Epilepsia 47:1253–1284CrossRef
17.
Zurück zum Zitat da Silveira MR, Mentenegro MA, Franzon RC et al (2006) Effectiveness of clobazam as add-on therapy in children with refractory focal epilepsy. Arq Neuropsiquiatr 64(3B):705–710CrossRef da Silveira MR, Mentenegro MA, Franzon RC et al (2006) Effectiveness of clobazam as add-on therapy in children with refractory focal epilepsy. Arq Neuropsiquiatr 64(3B):705–710CrossRef
18.
Zurück zum Zitat Conry JA, Ng YT, Kernitsky L et al (2014) Stable dosages of clobazam for Lennox-Gastaut syndrome are associated with sustained drop-seizure and total-seizure improvements over 3 years. Epilepsia 55(4):558–567CrossRef Conry JA, Ng YT, Kernitsky L et al (2014) Stable dosages of clobazam for Lennox-Gastaut syndrome are associated with sustained drop-seizure and total-seizure improvements over 3 years. Epilepsia 55(4):558–567CrossRef
19.
Zurück zum Zitat Hahn J, Lee H, Kang HC et al (2019) Clobazam as an adjunctive treatment for infantile spasms. Epilepsy Behav 95:161–165CrossRef Hahn J, Lee H, Kang HC et al (2019) Clobazam as an adjunctive treatment for infantile spasms. Epilepsy Behav 95:161–165CrossRef
20.
Zurück zum Zitat Chiron C, Marchand MC, Tran A et al (2000) Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome dedicated trial STICLO study group. Lancet 356:1638–1642CrossRef Chiron C, Marchand MC, Tran A et al (2000) Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome dedicated trial STICLO study group. Lancet 356:1638–1642CrossRef
21.
Zurück zum Zitat Nickels K, Thibert R, Rau S et al (2018) How do we diagnose and treat epilepsy with myoclonic-atonic seizures (Doose syndrome)? Results of the Pediatric Epilepsy Research Consortium survey. Epilepsy Res 144:14–19CrossRef Nickels K, Thibert R, Rau S et al (2018) How do we diagnose and treat epilepsy with myoclonic-atonic seizures (Doose syndrome)? Results of the Pediatric Epilepsy Research Consortium survey. Epilepsy Res 144:14–19CrossRef
22.
Zurück zum Zitat van den Munckhof B, Alderweireld C, Davelaar S et al (2018) Treatment of electrical status epilepticus in sleep: Clinical and EEG characteristics and response to treatments in 47 patients. Eur J Paediatr Neurol 22(1):64–71CrossRef van den Munckhof B, Alderweireld C, Davelaar S et al (2018) Treatment of electrical status epilepticus in sleep: Clinical and EEG characteristics and response to treatments in 47 patients. Eur J Paediatr Neurol 22(1):64–71CrossRef
23.
Zurück zum Zitat Conry JA, Ng YT, Paolicchi JM et al (2009) Clobazam in the treatment of Lennox-Gastaut syndrome. Epilepsia 50(5):1158–1166CrossRef Conry JA, Ng YT, Paolicchi JM et al (2009) Clobazam in the treatment of Lennox-Gastaut syndrome. Epilepsia 50(5):1158–1166CrossRef
24.
Zurück zum Zitat Isojarvi J, Gidal BE, Chung S, Wechsler RT (2018) Optimizing clobazam treatmentinpatientswithLennox-Gastautsyndrome. Epilepsy Behav 78(1):149–154CrossRef Isojarvi J, Gidal BE, Chung S, Wechsler RT (2018) Optimizing clobazam treatmentinpatientswithLennox-Gastautsyndrome. Epilepsy Behav 78(1):149–154CrossRef
25.
Zurück zum Zitat Gedela S, Freedman DA, Gedela S et al (2019) Safetyandefficacyofsupratherapeuticdosesof Clobazam. J Child Neurol 34(12):735–738CrossRef Gedela S, Freedman DA, Gedela S et al (2019) Safetyandefficacyofsupratherapeuticdosesof Clobazam. J Child Neurol 34(12):735–738CrossRef
26.
Zurück zum Zitat Gidal BE, Wechsler RT, Sankar R et al (2016) Deconstructing tolerance with clobazam: Post hoc analyses from an open-label extension study. Neurology 87(17):1806–1812CrossRef Gidal BE, Wechsler RT, Sankar R et al (2016) Deconstructing tolerance with clobazam: Post hoc analyses from an open-label extension study. Neurology 87(17):1806–1812CrossRef
27.
Zurück zum Zitat Walzer M, Bekersky I, Blum RA, Tolbert D (2012) Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome p450 isoenzymes. Pharmacotherapy 32(4):340–353CrossRef Walzer M, Bekersky I, Blum RA, Tolbert D (2012) Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome p450 isoenzymes. Pharmacotherapy 32(4):340–353CrossRef
28.
Zurück zum Zitat Renfroe JB, Jouko I, Lee D (2015) Somnolence and sedation were transient adverse events for most patients receiving clobazam therapy: post hoc analysis of trial OV-1012 data. J Neurol Res 5(4–5):252–256CrossRef Renfroe JB, Jouko I, Lee D (2015) Somnolence and sedation were transient adverse events for most patients receiving clobazam therapy: post hoc analysis of trial OV-1012 data. J Neurol Res 5(4–5):252–256CrossRef
Metadaten
Titel
CLB add-on treatment in patients with epileptic encephalopathy: a single center experience with long-term follow-up
verfasst von
Dilşad Türkdoğan
Gülten Öztürk
Publikationsdatum
29.03.2021
Verlag
Springer International Publishing
Erschienen in
Acta Neurologica Belgica / Ausgabe 1/2022
Print ISSN: 0300-9009
Elektronische ISSN: 2240-2993
DOI
https://doi.org/10.1007/s13760-021-01606-4

Kompaktes Leitlinien-Wissen Neurologie (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Neu im Fachgebiet Neurologie

Ein pulverisierter Plastiklöffel im Gehirn

Das menschliche Gehirn besteht zu etwa 0,5% aus Nanoplastik – Tendenz weiter steigend. Nach Resultaten eine Autopsiestudie reichert sich Plastik im Gehirn 10- bis 30-fach stärker an als in anderen Organen – mit bislang noch völlig unklaren Folgen.

Schlaganfall durch wandernde A. carotis interna

Die Thrombolyse nützte nichts, vielmehr war eine Teilresektion des Zungenbeins nötig: Es hatte eine verlagerte Carotis interna komprimiert und so bei einem älteren Mann einen Schlaganfall ausgelöst. Per Bildgebung lässt sich eine solche Ursache manchmal nur schwer nachweisen.

Epileptischer Anfall nach Darmreinigung

Die Darmreinigung vor einer Koloskopie führte einen älteren Mann auf die Intensivstation: Seine Natriumwerte waren durch die Prozedur so gesunken, dass er Bewusstseinstrübungen und Krampfanfälle entwickelte.

Welche Faktoren das Demenzrisiko bei Vorhofflimmern beeinflussen

In einer Metaanalyse wurden elf Faktoren identifiziert, die bei Vorhofflimmern(VHF)-Patienten mit dem Risiko für eine kognitive Beeinträchtigung assoziiert sind. Im besten Fall eröffnet sich damit ein Weg für die Prävention.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.